Beta Drugs Key Ratios
NSE: BETA
₹2,201.00
₹6.80
(0.31%)
As on 28-Aug-2026IST
Market cap
₹2,448 Cr
Revenue (TTM)
₹362 Cr
P/E Ratio
59
P/B Ratio
5.8
Div. Yield
0 %
Key Ratios and Highlights
| Growth Score (%) | Quarterly | Annual (TTM) | |||
|---|---|---|---|---|---|
| Particulars | QoQ | YoY | 1-Year | 3-Years | 5-Years |
| Revenue | 33.61 | 25.29 | 22.54 | 25.38 | 31.89 |
| EBIT | 78.71 | 44.07 | 23.65 | 20.55 | 34.42 |
| Net Profit | 74.60 | 35.06 | 16.42 | 19.55 | 35.13 |
| EPS | 59.68 | 23.00 | 16.42 | 19.55 | 35.13 |
| Book Value | -- | -- | 25.44 | 28.75 | 28.11 |
| Key Ratios (%) | Average | Annual (TTM) | |||
|---|---|---|---|---|---|
| Particulars | 3-Years | 5-Years | Mar-25 | Mar-24 | Mar-23 |
| EBIT-Margin
| 13.77 | 17.52 | 17.14 | 16.98 | 18.81 |
| Net Margin
| 9.89 | 12.15 | 11.50 | 12.27 | 13.48 |
| Return on equity
| 18.31 | 25.60 | 23.95 | 26.03 | 28.55 |
| Return on Capital
| 22.91 | 30.09 | 25.23 | 32.74 | 33.94 |
| Return on Assets
| 11.75 | 14.43 | 11.99 | 15.63 | 16.74 |
| Debt to Equity (x)
| -- | -- | 0.70 | 0.09 | 0.17 |
Profitability
ROCE
25.23
Higher than Peers by 10.51
Earning before interest and taxes / (Average net worth + Average total Debt) * 100
|
Company Name
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
Mar-21
|
|---|---|---|---|---|---|
|
Beta Drugs
|
25.23
|
32.74
|
33.94
|
36.38
|
22.17
|
|
Peer Median
|
14.72
|
18.85
|
11.60
|
11.89
|
--
|
ROE
23.95
Higher than Peers by 12.28
Profit after tax / Average Net worth * 100
|
Company Name
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
Mar-21
|
|---|---|---|---|---|---|
|
Beta Drugs
|
23.95
|
26.03
|
28.55
|
30.85
|
18.65
|
|
Peer Median
|
11.67
|
14.92
|
11.46
|
13.43
|
--
|
ROA
11.99
Higher than Peers by 4.13
Profit after tax / Average Total assets * 100
|
Company Name
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
Mar-21
|
|---|---|---|---|---|---|
|
Beta Drugs
|
11.99
|
15.63
|
16.74
|
17.53
|
10.26
|
|
Peer Median
|
7.86
|
9.06
|
6.44
|
7.03
|
--
|
EBIT Margin
17.14
Higher than Peers by 2.10
Operating profit (EBIT) / Net Sales * 100
|
Company Name
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
Mar-21
|
|---|---|---|---|---|---|
|
Beta Drugs
|
17.14
|
16.98
|
18.81
|
19.28
|
15.39
|
|
Peer Median
|
15.03
|
14.71
|
12.37
|
16.50
|
--
|
Net Margin
11.50
Higher than Peers by 2.17
Net profit / Total Income (Net sales plus other income) * 100
|
Company Name
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
Mar-21
|
|---|---|---|---|---|---|
|
Beta Drugs
|
11.50
|
12.27
|
13.48
|
13.45
|
10.05
|
|
Peer Median
|
9.33
|
8.49
|
10.02
|
10.49
|
--
|
Cash Profit Margin
15.16
--
(Net profit + Depreciation) / Gross Sales * 100
|
Company Name
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
Mar-21
|
|---|---|---|---|---|---|
|
Beta Drugs
|
15.16
|
15.63
|
18.11
|
17.45
|
16.02
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Revenue Growth
22.54
Higher than Peers by 12.27
Year on year growth in net sales
|
Company Name
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
Mar-21
|
|---|---|---|---|---|---|
|
Beta Drugs
|
22.54
|
30.21
|
23.54
|
58.31
|
27.88
|
|
Peer Median
|
10.27
|
11.85
|
9.08
|
13.45
|
--
|
EBIT Growth
23.65
Lower than Peers by 0.50
Year on year growth in operating profit (EBIT)
|
Company Name
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
Mar-21
|
|---|---|---|---|---|---|
|
Beta Drugs
|
23.65
|
17.55
|
20.52
|
98.35
|
26.30
|
|
Peer Median
|
24.15
|
28.00
|
-3.12
|
18.27
|
--
|
Net Profit Growth
16.42
Lower than Peers by 13.88
Year on year growth in profit after tax
|
Company Name
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
Mar-21
|
|---|---|---|---|---|---|
|
Beta Drugs
|
16.42
|
18.62
|
23.73
|
111.76
|
24.53
|
|
Peer Median
|
30.29
|
36.51
|
-0.85
|
27.20
|
--
|
EPS Growth
16.42
Lower than Peers by 8.09
Year on year growth in earnings per share
|
Company Name
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
Mar-21
|
|---|---|---|---|---|---|
|
Beta Drugs
|
16.42
|
18.62
|
23.73
|
111.76
|
24.53
|
|
Peer Median
|
24.50
|
--
|
-6.82
|
16.28
|
--
|
Book Value Growth
25.45
--
Year on year growth in book value per share
|
Company Name
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
Mar-21
|
|---|---|---|---|---|---|
|
Beta Drugs
|
25.45
|
27.86
|
33.07
|
34.58
|
20.14
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Solvency
Debt to Equity
0.70
Higher than Peers by 0.47
Total debt / Net worth
|
Company Name
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
Mar-21
|
|---|---|---|---|---|---|
|
Beta Drugs
|
0.70
|
0.09
|
0.17
|
0.22
|
0.25
|
|
Peer Median
|
0.23
|
0.20
|
0.15
|
0.15
|
--
|
Short term debt to equity ratio
0.03
--
(Short term borrowings / Net worth)
|
Company Name
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
Mar-21
|
|---|---|---|---|---|---|
|
Beta Drugs
|
0.03
|
0.03
|
0.07
|
0.05
|
0.05
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Current Ratio
3.01
Higher than Peers by 1.22
Current Assets / Current Liabilities and Provisions
|
Company Name
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
Mar-21
|
|---|---|---|---|---|---|
|
Beta Drugs
|
3.01
|
1.99
|
1.93
|
1.88
|
1.95
|
|
Peer Median
|
1.79
|
1.96
|
2.08
|
1.89
|
--
|
Quick Ratio
2.49
Higher than Peers by 1.02
(Current Assets - Inventory) / Current Liabilities and Provisions
|
Company Name
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
Mar-21
|
|---|---|---|---|---|---|
|
Beta Drugs
|
2.49
|
1.55
|
1.49
|
1.47
|
1.57
|
|
Peer Median
|
1.47
|
1.44
|
1.58
|
1.64
|
--
|
Interest Coverage
9.15
Lower than Peers by 0.27
Earning before interest and taxes (EBIT) / Interest Expenses
|
Company Name
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
Mar-21
|
|---|---|---|---|---|---|
|
Beta Drugs
|
9.15
|
18.29
|
18.00
|
19.06
|
7.59
|
|
Peer Median
|
9.42
|
8.58
|
15.41
|
15.38
|
--
|
Operating Efficiency
Debtors to sales
28.31
Higher than Peers by 2.49
Debtors outstanding / Net Sales * 100
|
Company Name
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
Mar-21
|
|---|---|---|---|---|---|
|
Beta Drugs
|
28.31
|
26.80
|
27.62
|
24.58
|
29.17
|
|
Peer Median
|
25.82
|
26.12
|
22.96
|
20.72
|
--
|
Asset Turnover
1.02
Higher than Peers by 0.27
Sales / Average Total Assets
|
Company Name
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
Mar-21
|
|---|---|---|---|---|---|
|
Beta Drugs
|
1.02
|
1.27
|
1.24
|
1.30
|
1.02
|
|
Peer Median
|
0.75
|
0.77
|
0.65
|
0.61
|
--
|
Receivable days
91.57
--
Average Debtors / Sales * 365
|
Company Name
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
Mar-21
|
|---|---|---|---|---|---|
|
Beta Drugs
|
91.57
|
87.61
|
86.71
|
78.48
|
103.42
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Inventory Days
55.19
--
Average Inventory / Sales * 365
|
Company Name
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
Mar-21
|
|---|---|---|---|---|---|
|
Beta Drugs
|
55.19
|
49.64
|
42.67
|
38.24
|
44.62
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Payable days
139.01
--
Average Creditors / Cost of goods sold * 365
|
Company Name
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
Mar-21
|
|---|---|---|---|---|---|
|
Beta Drugs
|
139.01
|
121.55
|
124.66
|
101.32
|
108.61
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Cash Conversion Cycle
7.75
--
Receivable Days + Inventory Days - Payable Days
|
Company Name
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
Mar-21
|
|---|---|---|---|---|---|
|
Beta Drugs
|
7.75
|
15.70
|
4.72
|
15.40
|
39.42
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Valuation
Price / Earnings
45.35
Higher than Peers by 5.64
Current share price divided by earning per share in the last twelve months
|
Company Name
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
Mar-21
|
|---|---|---|---|---|---|
|
Beta Drugs
|
45.35
|
31.00
|
19.62
|
21.90
|
9.84
|
|
Peer Median
|
39.70
|
33.48
|
37.74
|
60.11
|
--
|
Price / Book Value
9.76
Higher than Peers by 6.04
Current share price divided by book value per share in the latest financial year
|
Company Name
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
Mar-21
|
|---|---|---|---|---|---|
|
Beta Drugs
|
9.76
|
7.55
|
4.90
|
5.89
|
1.68
|
|
Peer Median
|
3.72
|
4.21
|
3.22
|
3.92
|
--
|
Dividend Yield
--
--
Dividend per share in the past twelve months divided by current share price
|
Company Name
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
Mar-21
|
|---|---|---|---|---|---|
|
Beta Drugs
|
--
|
--
|
--
|
--
|
--
|
|
Peer Median
|
0.16
|
0.21
|
0.57
|
0.56
|
--
|
EV/EBITDA
23.62
Lower than Peers by 6.60
Enterprise Value (Current Market Capitalisation + Total Debt - Cash & Equivalents) / Earnings before interest, taxes, depreciation and taxes (EBITDA)
|
Company Name
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
Mar-21
|
|---|---|---|---|---|---|
|
Beta Drugs
|
23.62
|
19.10
|
11.21
|
12.59
|
4.85
|
|
Peer Median
|
30.23
|
29.90
|
28.81
|
25.94
|
--
|
Market Cap
1,924
Lower than Peers by 2,927
Current Share price multiplied by latest total number of shares outstanding
|
Company Name
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
Mar-21
|
|---|---|---|---|---|---|
|
Beta Drugs
|
1,924
|
1,186
|
603
|
544
|
115
|
|
Peer Median
|
4,851
|
2,099
|
15,272
|
13,501
|
--
|
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.
